4.01.2011

Euromedic to divest its dialysis business to Fresenius Medical Care in order to focus on Diagnostics and Cancer Treatment

Amsterdam, Netherlands – Euromedic International, the Pan-European leader in medical services, today announces that it has signed a definitive agreement to divest International Dialysis Centres (“IDC”), its dialysis care business, to Fresenius Medical Care AG & Co, the world’s largest provider of dialysis products and services.

The sale of IDC forms part of Euromedic’s broader strategy to focus on its leading markets positions in the field of diagnostics and cancer treatment. The purchase price will be €485 million. The transaction remains subject to receipt of all necessary regulatory approvals and is expected to close over the coming months.

Euromedic is the largest provider of dialysis services in Eastern Europe, treating over 8,200 patients in 9 countries. Fresenius Medical Care, the world leader in renal therapy, currently serves more than 210,000 patients globally and more than 17,000 patients in Eastern Europe.

Commenting on the transaction, Richard di Benedetto, Chief Executive Officer of Euromedic, said: "We are very proud of what we have built up in the dialysis services space. This transaction is testimony to the tremendous skills and high quality of our IDC employees and the impeccable service afforded our patients. We strongly believe that Fresenius Medical Care will be an excellent home for IDC and will enable IDC to build on its current strength across Eastern Europe and to continue its long standing track record of success. In addition, this transaction will allow Euromedic to fully dedicate time and resources to materially advance our European market leading positions in the highly attractive fields of diagnostics and cancer treatment.”

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, said: “Eastern Europe is a key component of our overall growth strategy, and we are convinced that Euromedic’s HD operations will be an excellent fit with those of Fresenius Medical Care. Bringing together the experienced HD teams of both companies and our focus on high-quality patient care will give us a unique opportunity to meet the growing needs of the public sector in these fast growing markets.”

Bank of America Merrill Lynch is acting as exclusive financial adviser to Euromedic on this transaction. Linklaters and White & Case are serving as legal counsel.

Note to Editors:

About Euromedic International
Euromedic owns and operates a pan-European network of more than 140 Medical Centres including 101 Diagnostics, 39 Clinical Laboratories and three Cancer Treatment Centres in 12 countries across Europe. It is jointly owned by BAML Capital Partners, Montagu and Ares Life Sciences.

About BAML Capital Partners
BAML Capital Partners is the private equity arm of Bank of America Corporation and led the equity syndicate in both the original Euromedic private equity transaction in 2008 and this transaction. Bank of America is one of the world's largest financial institutions, serving clients in more than 150 countries. Bank of America Corporation stock (NYSE: BAC) is a component of the Dow Jones Industrial Average and is listed on the New York Stock Exchange.

For further information on BAML Capital Partners, please visit www.bankofamerica.com/bamlcp.

About Ares Life Sciences
Ares Life Sciences is a healthcare-focused investment firm, whose financial backer is the Bertarelli family. Its strategy is to focus on key life sciences sectors, mainly: pharmaceuticals and biotechnology, medical diagnostics, and medical technology. Ares Life Sciences has a long-term view on investments and a core element of its investment strategy is to make available to its portfolio companies the collective experience and network of its team. Ares Life Sciences' portfolio includes investments in Esaote, Euromedic and Stallergenes.

For further information on Ares Life Sciences, please visit http://www.areslifesciences.com/.

About Montagu
Montagu is one of Europe’s leading private equity advisors. Headquartered in London, Montagu also has offices in Düsseldorf, Manchester, Paris, Stockholm and Warsaw. Founded in 1968, Montagu can look back on 40 years’ experience in investing in more than 400 transactions. The primary investment focus of Montagu is on management-buy-out transactions and companies that operate in stable niche markets with a transaction value ranging from €100 million to €1 billion. Montagu has over €3.5 billion of funds and assets under management.

For further information on Montagu, please visit www.montagu.com.

Download PDF
(23.2Ko)

< Back to list ^ Top of the page